These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. De Bac C; Grimaldi F; Clementi C; Duca F; Livoli D; Taliani G Gut; 1993; 34(2 Suppl):S135. PubMed ID: 8314480 [TBL] [Abstract][Full Text] [Related]
26. Interferon alfa for chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and predictors of response. Hope RL; Weltman M; Dingley J; Fiatarone J; Hope AH; Craig PI; Grierson JM; Bilous M; Williams SJ; Farrell GC Med J Aust; 1995 Jan; 162(1):8-11. PubMed ID: 7845310 [TBL] [Abstract][Full Text] [Related]
27. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007 [TBL] [Abstract][Full Text] [Related]
28. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508 [TBL] [Abstract][Full Text] [Related]
29. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984 [TBL] [Abstract][Full Text] [Related]
30. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin. Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916 [TBL] [Abstract][Full Text] [Related]
31. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224 [TBL] [Abstract][Full Text] [Related]
32. Serum hepatitis C virus RNA levels in chronic hepatitis C--importance for outcome of interferon alfa-2b treatment. Yun ZB; Reichard O; Chen M; Lundeberg J; Norkrans G; Fryden A; Sönnerborg A; Weiland O Scand J Infect Dis; 1994; 26(3):263-70. PubMed ID: 7939425 [TBL] [Abstract][Full Text] [Related]
33. Treatment of chronic hepatitis D with interferon alfa-2a. Farci P; Mandas A; Coiana A; Lai ME; Desmet V; Van Eyken P; Gibo Y; Caruso L; Scaccabarozzi S; Criscuolo D N Engl J Med; 1994 Jan; 330(2):88-94. PubMed ID: 8259188 [TBL] [Abstract][Full Text] [Related]
34. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP; McHutchison JG; Gordon SC; Rustgi VK; Shiffman M; Reindollar R; Goodman ZD; Koury K; Ling M; Albrecht JK Lancet; 2001 Sep; 358(9286):958-65. PubMed ID: 11583749 [TBL] [Abstract][Full Text] [Related]
35. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. Fernández JL; Rendo P; del Pino N; Viola L J Viral Hepat; 1997 Mar; 4(2):113-9. PubMed ID: 9097267 [TBL] [Abstract][Full Text] [Related]
36. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype. Fried MW; Shiffman M; Sterling RK; Weinstein J; Crippin J; Garcia G; Wright TL; Conjeevaram H; Reddy KR; Peter J; Cotsonis GA; Nolte FS Am J Gastroenterol; 2000 Nov; 95(11):3225-9. PubMed ID: 11095346 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ascione A; De Luca M; Canestrini C; Di Costanzo GG; Raimondo G; Longo G; Manns MP; Tillmann HL; Forte GB; Rocco P; Biceglia O; Faleo D; Vinelli F; Cela EM; Amitrano L; Addario L; Gigliotti T Ital J Gastroenterol Hepatol; 1998 Oct; 30(5):517-23. PubMed ID: 9836109 [TBL] [Abstract][Full Text] [Related]
38. Prednisolone withdrawal followed by recombinant alfa-interferon in chronic non-A, non-B hepatitis: interim results of a randomized controlled trial. Liaw YF; Sheen IS; Lin SM; Chen TJ Gastroenterol Jpn; 1991 Jul; 26 Suppl 3():247-50. PubMed ID: 1909274 [TBL] [Abstract][Full Text] [Related]
39. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. Schvarcz R; Ando Y; Sönnerborg A; Weiland O J Hepatol; 1995; 23 Suppl 2():17-21. PubMed ID: 8720289 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Fried MW; Peter J; Hoots K; Gaglio PJ; Talbut D; Davis PC; Key NS; White GC; Lindblad L; Rickles FR; Abshire TC Hepatology; 2002 Oct; 36(4 Pt 1):967-72. PubMed ID: 12297845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]